Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18664876 | LACTIPLANTIBACILLUS PLANTARUM FOR DEGRADING TANNINS AND SAPONINS, AND USE THEREOF | May 2024 | July 2025 | Allow | 14 | 2 | 1 | No | No |
| 18400012 | MILBEMYCIN STRAIN WITH HIGH-YIELD AND ITS APPLICATION | December 2023 | July 2025 | Allow | 19 | 2 | 0 | Yes | No |
| 17982726 | Compositions And Methods To Reduce And/Or Dissolve Calcium Deposits In Arterial Walls | November 2022 | August 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18051856 | ENGINEERED LEUCINE DECARBOXYLASES | November 2022 | August 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 18049978 | VARIANT SULFATASE ENZYMES WITH ENHANCED PROPERTIES | October 2022 | April 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 17823527 | METHODS FOR TREATING MULTIDRUG RESISTANT BREAST CANCER | August 2022 | March 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 17812030 | FRET Biosensor for Detecting and Reporting NAD+/NADH Ratio Changes | July 2022 | April 2025 | Allow | 33 | 3 | 1 | Yes | No |
| 17854594 | MONOMERIC FUSION PEPTIDES AND METHOD OF USE THEREOF | June 2022 | August 2024 | Abandon | 26 | 1 | 1 | Yes | No |
| 17764927 | MMUP MONOMER VARIANT AND APPLICATION THEREOF | March 2022 | January 2026 | Abandon | 46 | 0 | 1 | No | No |
| 17641429 | SPLIT INTEIN AND PREPARATION METHOD FOR RECOMBINANT POLYPEPTIDE USING THE SAME | March 2022 | January 2026 | Abandon | 46 | 0 | 1 | No | No |
| 17636724 | CONVERSION METHOD, CONVERSION AGENT, METHOD FOR PRODUCING ROYAL JELLY COMPOSITION, AND LACTOBACILLUS BACTERIA | February 2022 | December 2024 | Allow | 34 | 2 | 0 | Yes | No |
| 17631800 | OXIDATION-RESISTANT SERPINS | January 2022 | December 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17584658 | COMBINATION STIRRER | January 2022 | October 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17584133 | T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | January 2022 | February 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17628079 | COMPOSITIONS AND METHODS FOR TREATING SKIN CONDITIONS | January 2022 | February 2026 | Abandon | 49 | 1 | 1 | No | No |
| 17625158 | COMPOSITION FOR PREVENTING OR TREATING URIC ACID-RELATED DISEASE | January 2022 | May 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17625046 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE | January 2022 | January 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17544908 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | December 2021 | August 2024 | Allow | 32 | 2 | 0 | Yes | No |
| 17593910 | TREATMENT OF RESPIRATORY DISEASES WITH A BACTERIUM OF THE GENUS LACTOBACILLUS | November 2021 | August 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17610398 | Methods And Compositions For Treating Liver Disorders | November 2021 | August 2025 | Abandon | 45 | 2 | 1 | Yes | No |
| 17594643 | METABOLIC ENGINEERING OF NON-PATHOGENIC ESCHERICHIA COLI STRAINS FOR THE CONTROLLED PRODUCTION OF LOW MOLECULAR WEIGHT HEPAROSAN AND SIZE-SPECIFIC HEPAROSAN OLIGOSACCHARIDES | October 2021 | January 2025 | Abandon | 39 | 2 | 1 | Yes | No |
| 17604896 | MODIFIED POLYPEPTIDE OF GLUTAMINE SYNTHETASE AND METHOD OF PRODUCING L-GLUTAMINE USING THE SAME | October 2021 | December 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17603917 | ADENINE BASE EDITORS WITH REDUCED OFF-TARGET EFFECTS | October 2021 | July 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17599818 | MICROORGANISM PRODUCING L-AMINO ACID AND METHOD OF PRODUCING L-AMINO ACID USING THE SAME | September 2021 | October 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17440027 | USE OF A MANGANESE SUPEROXIDE DISMUTASE WITH HIGH STABILITY IN THE PREVENTION OR TREATMENT OF CEREBRAL STROKE | September 2021 | July 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17476030 | STREPTOCOCCUS BACTERIOPHAGE LYSINS FOR DETECTION AND TREATMENT OF GRAM POSITIVE BACTERIA | September 2021 | November 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17435541 | COMPOSITIONS AND METHODS FOR TREATING ACNE | September 2021 | March 2026 | Abandon | 54 | 3 | 1 | No | No |
| 17431185 | PHYTASE MUTANT | August 2021 | May 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17401278 | Methods for Discovery of Antimicrobial Compounds | August 2021 | November 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17428676 | METHOD AND COMPOSITION MATTER FOR IMMUNOPROTEASOME-MEDIATED DELIVERY INTO LIVING CELLS | August 2021 | July 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17424605 | METHODS FOR PURIFYING ANTIBODIES COMPRISING OF A PROCESS BY USING ACTIVATED CARBON MATERIALS | July 2021 | September 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17420411 | DIETARY EARLY GLYCATION PRODUCTS FOR TREATING AND PREVENTING AUTOIMMUNE DISEASES | July 2021 | April 2025 | Abandon | 45 | 1 | 1 | Yes | No |
| 17419079 | NOVEL ACETYL-TRANSFERASES | June 2021 | February 2026 | Allow | 56 | 3 | 1 | Yes | No |
| 17418730 | INSULIN PRECURSOR PURIFYING METHOD USING ANION EXCHANGE CHROMATOGRAPHY | June 2021 | May 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17297255 | Antimicrobial Susceptibility Assay and Kit | May 2021 | March 2025 | Abandon | 45 | 1 | 1 | Yes | No |
| 17287232 | METHODS, APPARATUS AND KITS FOR BACTERIAL CELL LYSIS | April 2021 | June 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17286098 | PROCESS FOR PURIFYING C1-INH | April 2021 | February 2026 | Abandon | 58 | 4 | 0 | Yes | No |
| 17284772 | PHOSPHATE TRANSLOCATOR | April 2021 | May 2025 | Abandon | 50 | 2 | 1 | Yes | No |
| 17284142 | HEPATITIS B VIRUS REPLICATION INHIBITOR AND PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS B COMPRISING THE SAME | April 2021 | February 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17279498 | OVER EXPRESSION OF RIBONUCLEOTIDE REDUCTASE INHIBITOR IN YEAST FOR INCREASED ETHANOL PRODUCTION | March 2021 | August 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17275821 | NOVEL PRO-INSULIN ASPART STRUCTURE AND METHOD FOR PREPARING INSULIN ASPART | March 2021 | March 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17273363 | Methods for separation of chlorophyll and soluble proteins | March 2021 | February 2025 | Abandon | 48 | 1 | 1 | Yes | No |
| 17271339 | CHONDROINDUCTIVE PEPTIDES AND COMPOSITIONS AND METHODS OF USE THEREOF | February 2021 | April 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17264531 | VARIANT ALPHA-AMYLASES HAVING AMINO ACID SUBSTITUTIONS THAT LOWER THE PKA OF THE GENERAL ACID | January 2021 | July 2025 | Allow | 54 | 2 | 1 | No | No |
| 17256566 | SEPARATING AGENT | December 2020 | November 2024 | Allow | 47 | 2 | 1 | Yes | No |
| 16981352 | ANTIGENIC PEPTIDES DERIVING FROM SECRETOGRANIN V AND USES THEREOF FOR THE DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES | September 2020 | August 2025 | Allow | 59 | 5 | 1 | Yes | No |
| 17018751 | PEPTIDE TAG AND TAGGED PROTEIN INCLUDING SAME | September 2020 | April 2025 | Allow | 55 | 6 | 1 | Yes | No |
| 16621549 | METHODS AND COMPOSITIONS FOR TREATING CANCER | December 2019 | October 2025 | Allow | 60 | 2 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner ESPINOSA, CLAUDIA EDILMA works in Art Unit 1654 and has examined 31 patent applications in our dataset. With an allowance rate of 48.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.
Examiner ESPINOSA, CLAUDIA EDILMA's allowance rate of 48.4% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ESPINOSA, CLAUDIA EDILMA receive 1.97 office actions before reaching final disposition. This places the examiner in the 49% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by ESPINOSA, CLAUDIA EDILMA is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +56.7% benefit to allowance rate for applications examined by ESPINOSA, CLAUDIA EDILMA. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 30.8% of applications are subsequently allowed. This success rate is in the 61% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 30.8% of cases where such amendments are filed. This entry rate is in the 44% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.